Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer Communications

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3727/095535491820873740PMID 1722107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human monocytes selectively bind to cells expressing the tumorigenic phenotype

  2004cited by this paper
• Phase I Trial of ImmTher, a New Liposome‐Incorporated Lipophilic Disaccharide Tripeptide

  1991cited by this paper
• Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals.

  1991cited by this paper
• Interleukin 1 receptor blockade attenuates the host inflammatory response.

  1990cited by this paper
• Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.

  1990cited by this paper
• IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA.

  1990cited by this paper
• IL-1 secretion by macrophages. Enhancement of IL-1 secretion and processing by calcium ionophores.

  1990cited by this paper
• Substrate specificity of the protease that processes human interleukin-1 beta.

  1990cited by this paper
• Processing of precursor interleukin 1 beta and inflammatory disease.

  1990cited by this paper
• Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells.

  1990cited by this paper
• IL-1 beta is secreted by activated murine macrophages as biologically inactive precursor.

  1990cited by this paper
• Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.

  1989cited by this paper
• Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.

  1989cited by this paper
• Proteolysis of the native murine IL 1 beta precursor is required to generate IL 1 beta bioactivity.

  1989cited by this paper
• Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells.

  1989cited by this paper
• Cytotoxic liposomes: membrane interleukin 1 presented in multilamellar vesicles.

  1989cited by this paper
• Lithium Chloride Stimulates Human Monocytes to Secrete Tumor Necrosis Factor/Cachectin

  1989cited by this paper
• Identification of a monocyte specific pre-interleukin 1 beta convertase activity.

  1989cited by this paper
• Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.

  1989cited by this paper
• Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6.

  1989cited by this paper
• Human interleukin 1 beta is not secreted from hamster fibroblasts when expressed constitutively from a transfected cDNA

  1988cited by this paper
• Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: role in the induction of interleukin 6.

  1988cited by this paper
• The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta.

  1988cited by this paper
• Expression of membrane interleukin 1 by fibroblasts transfected with murine pro-interleukin 1 alpha cDNA.

  1988cited by this paper
• Interleukin-1 enhances murine granulopoiesis in vivo.

  1988cited by this paper
• Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs.

  1987cited by this paper
• Additive effects of interleukin 1 and tumour necrosis factor‐alpha on the accumulation of the three granulocyte and macrophage colony‐stimulating factor mRNAs in human endothelial cells.

  1987cited by this paper
• Subcellular localization of human monocyte interleukin 1: evidence for an inactive precursor molecule and a possible mechanism for IL 1 release.

  1987cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Induction of colony stimulating factor in vivo by recombinant interleukin 1 alpha and recombinant tumor necrosis factor alpha 1.

  1987cited by this paper
• B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line.

  1987cited by this paper
• Interleukin 1 release by human monocytes treated with liposome-encapsulated lipopolysaccharide.

  1987cited by this paper
• Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor.

  1986cited by this paper
• Recombinant human TNF induces production of granulocyte–monocyte colony-stimulating factor

  1986cited by this paper
• Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide.

  1986cited by this paper
• Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine

  1986cited by this paper
• Natural and recombinant human interleukin 1-beta is cytotoxic for human melanoma cells.

  1986cited by this paper
• Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

  1986cited by this paper
• Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

  1986cited by this paper
• Tumor necrosis factor (TNF).

  1985cited by this paper
• Human interleukin 1 is a cytocidal factor for several tumor cell lines.

  1985cited by this paper
• Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.

  1985cited by this paper
• Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

  1985cited by this paper
• Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.

  1983cited by this paper
• Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.

  1983cited by this paper
• Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells

  1983cited by this paper
• Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide.

  1982cited by this paper
• Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.

  1981cited by this paper
• In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes.

  1981cited by this paper
• Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.

  1980cited by this paper
• Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

  1974cited by this paper

• Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy

  2018cites this paper
• Managing sarcoma: where have we come from and where are we going?

  2017cites this paper
• Differential roles of inflammation and apoptosis in initiation of mid-gestational abortion in malaria-infected C57BL/6 and A/J mice.

  2015cites this paper
• Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?

  2014cites this paper
• Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

  2014cites this paper
• New treatment options for nonmetastatic osteosarcoma: focus on mifamurtide in adolescents

  2012cites this paper
• Mifamurtide

  2010cites this paper
• Mifamurtide in osteosarcoma--a practical review.

  2010cites this paper
• Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma

  2009cites this paper
• Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

  2006cites this paper
• Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

  2005cites this paper
• Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels

  2005cites this paper
• Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated myramyl-tripeptide-phosphatidylethanolamine

  2005cites this paper
• In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells

  1999cites this paper
• ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity

  1999cites this paper
• Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators.

  1998cites this paper
• CHAPTER 2.3 – Systemic activation of macrophages by liposomes containing synthetic immunomodulators for treatment of metastatic disease

  1998cites this paper
• Canine osteosarcoma: amputation and chemoimmunotherapy.

  1996cites this paper
• Human Monocytes/Macrophages Release TNF-α in Response to Ox-LDL

  1996cites this paper
• Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin.

  1996cites this paper
• Human monocytes/macrophages release TNF-alpha in response to Ox-LDL.

  1996cites this paper
• Cytokines as vaccine adjuvants. Current status and potential applications.

  1995cites this paper
• Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

  1995cites this paper
• Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.

  1995cites this paper
• Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice.

  1995cites this paper
• Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

  1995cites this paper
• Combination Therapy with Ifosfamide and Liposome‐Encapsulated Muramyl Tripeptide: Tolerability, Toxicity, and Immune Stimulation

  1995cites this paper
• Antitumor effects of liposomal IL1α and TNFα against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice

  1995cites this paper
• Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes.

  1995cites this paper
• Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

  1995cites this paper
• Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.

  1994cites this paper
• In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.

  1994cites this paper
• Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.

  1994cites this paper
• Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

  1994cites this paper
• In vitro TNF-α production and in vivo alteration of TNF-α RNA in mouse peritoneal macrophages after treatment with different bacterial derived agents

  1994cites this paper
• In vitro TNF-alpha production and in vivo alteration of TNF-alpha RNA in mouse peritoneal macrophages after treatment with different bacterial derived agents.

  1994cites this paper
• Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression

  1993influential citation
• Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.

  1993cites this paper
• Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide

  1993cites this paper
• Interaction of phospholipids with proteins and peptides. New advances III.

  1993cites this paper
• Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.

  1993cites this paper
• Interaction of phospholipids with proteins and peptides. New advances IV.

  1992cites this paper
• Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.

  1992cites this paper